KromaTiD Announces the Appointment of Vic Myer, PhD to its Board of Directors
Longmont, CO 9/28/2020 – KromaTiD, Inc. today announced the appointment of Vic Myer to its Board of Directors. Dr. Myer joins KromaTiD’s Board with extensive experience in biotechnology, R&D, building enterprise value, and pharmaceutical company executive leadership. He is currently Entrepreneur in Residence at Atlas Venture where he is involved in new company creation as well as working with existing Atlas portfolio companies. Prior to Atlas, Dr. Myer served for 5 years as Chief Technology Officer of Editas Medicine, a leading developer of gene editing-based therapies.
“We are pleased and excited to have Dr. Myer join our Board of Directors,” said KromaTiD Chief Executive Officer, Dr. Christopher Tompkins, “His assistance in 2019 and 2020 was instrumental in launching KromaTiD’s custom structural analytical services to the therapeutic gene editing market. We are looking forward to his technical and strategic insights as we expand and accelerate the company’s market presence through the launch of a powerful portfolio of offerings based on our dGH™ platform.”
Prior to Editas, Dr. Myer served over 10 years in various leadership roles within the Novartis Institutes for Biomedical Research (NIBR) in Cambridge, MA, including as executive director and site head for their Developmental and Molecular Pathways department. He also served in roles focused on leveraging and scaling omics technologies at Millennium, Akceli and Corning.
“KromaTiD’s dGH platform provides comprehensive measurements of structural rearrangements that occur during editing” said Dr. Myer, “This is essential data for understanding the outcomes of editing and risk to patients, and I am delighted to serve on the Board and help the company grow”
About KromaTiD
Based in Longmont, Colorado, KromaTiD develops and markets a full suite of best-in-class structural solutions to the engineered cells, undiagnosed diseases and oncology markets. The Company’s directional Genomic Hybridization product portfolio, which includes the targeted assays such as dGH in-Site™ and Pinpoint FISH™, as well the unbiased dGH SCREEN™, complement a wide variety of genomic analyses based on sequencing.